ARMPNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Armata Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$3.07−0.30 (-8.90%)
Close on Oct 19, 2026
- Market cap
- $190.47M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.33 (−9.71%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $190.47M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -13.54%
Fundamentals
- Net income
- -$192.18M
- EPS, diluted
- -$7.59
- Free cash flow
- -$25.79M
- Book value per share
- -$3.73
- Diluted shares
- 62M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$40.70M
Net income
-$192.18M
EPS, diluted
-$7.59
Free cash flow
-$25.79M
Reported periodTrailing twelve months